| Literature DB >> 33280997 |
Qingni Sang1, Qiangqiang Jia2, Hongyang Zhang3, Chuhui Lin1, Xiaodan Zhao1, Min Zhang4, Yuerong Wang1, Ping Hu5.
Abstract
Zhishi-Xiebai-Guizhi Decoction (ZSXBGZD), a traditional Chinese medicine (TCM) formula, has been used for treatment of coronary heart disease and myocardial infarction for nearly two thousand years. However, the chemical composition of ZSXBGZD is still unclear. In order to obtain the chemical profile of ZSXBGZD, an ultra-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS) method was utilized for the identification of its multi-constituents. As a result, a total of 148 compounds were identified based on their retention times, accurate masses and MS/MS data. In addition, an optimized UPLC fingerprint analysis, combined with chemometrics such as similarity analysis (SA), hierarchical cluster analysis (HCA), principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) was developed for quality assessment of ZSXBGZD. Multivariate data analysis revealed that samples could be classified correctly according to their geographic origins, and four compounds neohesperidin, naringin, guanosine and adenosine contributed the most to classification. The established UPLC method with multi-wavelength detection was further validated and implemented for simultaneous quantification of 12 representative ingredients in the prescription, including guanosine, adenosine, 2'-deoxyadenoside, syringin, magnoloside A, forsythoside A, naringin, hesperidin, cinnamaldehyde, neohesperidin, honokiol and magnolol. This is the first report on the comprehensive profiling of major chemical components in ZSXBGZD. The results of the study could help to uncover the chemical basis of ZSXBGZD and possess potential value for quality evaluation purpose.Entities:
Keywords: Chemical profiling; Chemometrics; UPLC fingerprint; UPLC-Q-TOF-MS; Zhishi-Xiebai-Guizhi Decoction
Mesh:
Substances:
Year: 2020 PMID: 33280997 DOI: 10.1016/j.jpba.2020.113771
Source DB: PubMed Journal: J Pharm Biomed Anal ISSN: 0731-7085 Impact factor: 3.935